Security Snapshot

Adaptive Biotechnologies Corp - Common Stock (ADPT) Institutional Ownership

CUSIP: 00650F109

13F Institutional Holders and Ownership History from Q3 2016 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

281

Shares (Excl. Options)

150,280,907

Price

$16.24

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
ADPT on Nasdaq
Shares outstanding
151,803,139
Price per share
$13.88
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
150,280,907
Total reported value
$2,440,621,109
% of total 13F portfolios
0%
Share change
+1,522,414
Value change
+$33,872,592
Number of holders
281
Price from insider filings
$13.88
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ADPT - Adaptive Biotechnologies Corp - Common Stock is tracked under CUSIP 00650F109.
  • 281 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 281 to 118 between Q4 2025 and Q1 2026.
  • Reported value moved from $2,440,621,109 to $391,169,606.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 281 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 00650F109?
CUSIP 00650F109 identifies ADPT - Adaptive Biotechnologies Corp - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Adaptive Biotechnologies Corp - Common Stock (ADPT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.9% +17% $194,757,356 +$33,318,016 11,992,448 +21% BlackRock, Inc. 31 Dec 2025
Sumitomo Mitsui Trust Group, Inc. 4.6% $53,981,782 6,833,137 Sumitomo Mitsui Trust Group, Inc. 31 Dec 2024
Nikko Asset Management Americas, Inc. 4.6% $53,981,782 6,833,137 Nikko Asset Management Americas, Inc. 31 Dec 2024
INTEGRATED CORE STRATEGIES (US) LLC 4.3% $49,711,809 6,292,634 Millennium Management LLC 31 Dec 2024
Rubric Capital Management LP 4.1% $72,889,139 6,256,847 Rubric Capital Management LP 30 Jun 2025
ARK Investment Management LLC 2.9% -27% $40,863,635 -$15,506,311 4,398,669 -28% ARK Investment Management LLC 31 May 2025

As of 31 Dec 2025, 281 institutional investors reported holding 150,280,907 shares of Adaptive Biotechnologies Corp - Common Stock (ADPT). This represents 99% of the company’s total 151,803,139 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Adaptive Biotechnologies Corp - Common Stock (ADPT) together control 73% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VIKING GLOBAL INVESTORS LP 20% 29,993,708 0% 1.3% $487,097,818
BlackRock, Inc. 8.8% 13,333,559 -0.18% 0% $216,536,989
VANGUARD GROUP INC 7.4% 11,282,152 +0.06% 0% $183,222,148
PRICE T ROWE ASSOCIATES INC /MD/ 2.9% 4,387,361 +303% 0.01% $71,252,000
WESTFIELD CAPITAL MANAGEMENT CO LP 2.7% 4,060,481 0.27% $65,942,211
GEODE CAPITAL MANAGEMENT, LLC 2.3% 3,511,855 +3.3% 0% $57,040,977
STATE STREET CORP 2.1% 3,181,644 +3.3% 0% $51,669,899
Invesco Ltd. 2% 3,107,653 +249% 0.01% $50,468,285
LORD, ABBETT & CO. LLC 2% 3,080,759 +151% 0.15% $50,032,000
GOLDMAN SACHS GROUP INC 1.9% 2,902,269 +54% 0.01% $47,132,848
Driehaus Capital Management LLC 1.8% 2,760,387 -8.6% 0.3% $44,828,685
JENNISON ASSOCIATES LLC 1.8% 2,674,668 +104% 0.03% $43,436,609
AMERIPRISE FINANCIAL INC 1.7% 2,590,984 -57% 0.01% $42,077,600
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.6% 2,422,089 -0.79% 0.02% $39,334,725
FRED ALGER MANAGEMENT, LLC 1.5% 2,245,418 -11% 0.14% $36,465,588
WELLINGTON MANAGEMENT GROUP LLP 1.4% 2,165,327 +332% 0.01% $35,164,911
ARK Investment Management LLC 1.4% 2,138,960 -32% 0.23% $34,736,718
Sumitomo Mitsui Trust Group, Inc. 1.3% 1,947,963 -47% 0.02% $31,634,919
Amova Asset Management Americas, Inc. 1.3% 1,947,963 -47% 0.37% $31,615,439
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 1.3% 1,940,376 0% 0.05% $31,512,000
D. E. Shaw & Co., Inc. 1.3% 1,902,685 +158% 0.02% $30,899,604
Aristotle Atlantic Partners, LLC 1.2% 1,842,444 -41% 1.4% $29,921,291
Blue Water Life Science Advisors, LP 1.2% 1,765,145 -18% 18% $28,665,955
DEUTSCHE BANK AG\ 1.1% 1,734,465 +1.2% 0.01% $28,167,711
PBU - The Pension Fund of Early Childhood & Youth Educators 1.1% 1,650,303 0% 0.39% $26,800,921

Institutional Holders of Adaptive Biotechnologies Corp - Common Stock (ADPT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 28,181,731 $391,169,606 -$55,794,101 $13.88 118
2025 Q4 150,280,907 $2,440,621,109 +$33,872,592 $16.24 281
2025 Q3 145,422,829 $2,175,120,073 -$14,779,461 $14.96 269
2025 Q2 148,178,882 $1,726,248,551 -$46,396,273 $11.65 240
2025 Q1 152,930,142 $1,136,093,247 +$68,698,942 $7.43 222
2024 Q4 143,282,424 $858,588,192 +$3,881,916 $6.00 204
2024 Q3 143,105,692 $732,467,776 -$27,674,373 $5.12 184
2024 Q2 148,655,164 $538,029,201 +$26,127,842 $3.62 173
2024 Q1 142,447,362 $456,622,976 -$10,170,998 $3.21 186
2023 Q4 143,639,172 $703,966,709 +$9,702,761 $4.90 194
2023 Q3 140,492,459 $765,707,625 +$15,429,772 $5.45 187
2023 Q2 137,082,822 $919,786,637 +$21,850,661 $6.71 208
2023 Q1 133,849,942 $1,179,397,231 +$14,000,370 $8.83 223
2022 Q4 132,787,161 $1,014,264,343 +$14,824,828 $7.64 216
2022 Q3 131,007,037 $931,519,109 -$31,344,186 $7.12 205
2022 Q2 134,391,278 $1,083,708,756 +$49,040,887 $8.09 196
2022 Q1 125,563,937 $1,741,620,797 -$42,426,089 $13.88 207
2021 Q4 123,444,543 $3,462,001,567 +$139,816,088 $28.06 208
2021 Q3 117,860,461 $4,003,739,752 -$434,478 $33.99 212
2021 Q2 117,427,979 $4,796,005,013 +$143,202,294 $40.86 226
2021 Q1 113,768,226 $4,579,995,207 -$122,834,155 $40.26 238
2020 Q4 114,044,316 $6,743,577,628 +$149,068,690 $59.13 244
2020 Q3 111,322,127 $5,410,179,736 +$503,359,137 $48.63 206
2020 Q2 101,046,823 $4,886,712,149 +$212,566,003 $48.38 192
2020 Q1 96,830,392 $2,689,585,555 +$284,953,611 $27.78 144
2019 Q4 86,210,177 $2,579,382,908 +$148,626,753 $29.92 129
2019 Q3 81,041,176 $2,492,319,624 +$38,889,817 $30.90 116
2019 Q2 78,228,081 $3,735,247,853 +$3,731,000,860 $48.30 110
2019 Q1 103,941 $4,247,000 $40.86 1
2016 Q4 0 $0 -$10,117 $13.88 0
2016 Q3 235 $10,117 +$10,117 $43.05 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .